Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?
Journal of Clinical Medicine · 30.04.2025 · 14 (9) · 3122
DOI: 10.3390/jcm14093122 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.04.2025. Verfasst von Maria Kałas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Medical University of Gdańsk, 80-214 Gdańsk, Poland. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs) have been one of the most discussed issues in medicine for the past few years. Initially dedicated to patients with type 2 diabetes mellitus (T2DM), the medicine turned out to be an effective weight-loss treatment for people beyond this population. Whereas their beneficial somatic and metabolic effect are beyond doubt, their possible psychiatric adverse reactions have raised concerns. Eating disorders (EDs) are among the mental illnesses whose number is increasing worldwide. Thus, this review aims to summarize the status of knowledge on the correlation between the popularity of GLP-1 RAs and EDs. The conclusions are not unequivocal, pointing out that GLP-1 ARs have the potential to be an effective therapeutic option in some cases of Eds, but if used inappropriately, may increase morbidity of eating disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
- Emergency Department, University Clinical Center, 80-952 Gdańsk, Poland.
ORCID-Profile: Maria Kałas, Mariusz Siemiński
Zitieren
APA
Kałas, M., Stępniewska, E., Gniedziejko, M., Leszczyński-Czeczatka, J., & Siemiński, M. (2025). Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?. Journal of Clinical Medicine, 14(9), 3122. https://doi.org/10.3390/jcm14093122
Vancouver
Kałas M, Stępniewska E, Gniedziejko M, Leszczyński-Czeczatka J, Siemiński M. Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?. Journal of Clinical Medicine. 2025;14(9):3122. doi:10.3390/jcm14093122
BibTeX
@article{Kaas2025,
author = {Kałas, Maria and Stępniewska, Ewelina and Gniedziejko, Michał and Leszczyński-Czeczatka, Jakub and Siemiński, Mariusz},
title = {Glucagon-like Peptide-1 Receptor Agonists in the Context of Eating Disorders: A Promising Therapeutic Option or a Double-Edged Sword?},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {9},
pages = {3122},
doi = {10.3390/jcm14093122}
}
EUVIMED